Regulus Therapeutics (NASDAQ:RGLS) Posts Quarterly Earnings Results, Meets Expectations

Regulus Therapeutics (NASDAQ:RGLS) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20), Zacks reports.

Regulus Therapeutics Stock Performance

NASDAQ:RGLS traded down $0.10 during mid-day trading on Thursday, reaching $1.38. The stock had a trading volume of 193,056 shares, compared to its average volume of 536,987. The firm has a market capitalization of $90.39 million, a price-to-earnings ratio of -1.29 and a beta of 1.41. Regulus Therapeutics has a twelve month low of $0.83 and a twelve month high of $3.00. The business has a 50 day simple moving average of $1.29 and a 200 day simple moving average of $1.47.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Insider Activity at Regulus Therapeutics

In other news, CEO Joseph P. Hagan sold 115,290 shares of Regulus Therapeutics stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $145,265.40. Following the completion of the sale, the chief executive officer now directly owns 222,572 shares in the company, valued at approximately $280,440.72. This trade represents a 34.12 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Preston Klassen sold 31,445 shares of Regulus Therapeutics stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $39,620.70. Following the sale, the insider now owns 36,055 shares of the company’s stock, valued at approximately $45,429.30. The trade was a 46.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 223,998 shares of company stock worth $282,237 over the last 90 days. Company insiders own 4.35% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.